Exhibit 5.1
June 19, 2013
Biodel Inc.
100 Saw Mill Road
Danbury, Connecticut 06810
Prospectus Supplement to Registration Statement on Form S-3
Ladies and Gentlemen:
This opinion is furnished to you in connection with (i) the Registration Statement on Form S-3 (File No. 333-188576) (the “Registration Statement”) filed by Biodel Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), for the purpose of registering, among other things, shares of the Company’s common stock, $0.01 par value per share (the “Common Stock”), which may be issued and sold by the Company from time to time on a delayed or continuous basis pursuant to Rule 415 under the Securities Act at an aggregate initial offering price not to exceed $75,000,000, as set forth in the Registration Statement and the base prospectus contained therein; and (ii) the prospectus supplement, dated June 19, 2013 (the “Prospectus Supplement”), relating to the issue and sale pursuant to the Registration Statement of up to 5,155,174 shares (the “Shares”) of Common Stock, including up to 672,414 Shares of Common Stock issuable upon exercise of an over-allotment option granted to the underwriters by the Company.
The Shares are to be issued and sold by the Company pursuant to the Underwriting Agreement, dated as of June 19, 2013 (the “Underwriting Agreement”), among the Company and the several underwriters named therein, for which William Blair & Company, L.L.C. is acting as representative. A copy of the Underwriting Agreement will be filed by the Company with the Commission as Exhibit 1.1 to the Company’s Current Report on Form 8-K, dated June 19, 2013.
We are acting as counsel for the Company in connection with the issue and sale by the Company of the Shares. We have examined a signed copy of the Registration Statement, as filed with the Commission, including the exhibits thereto, and the form of Prospectus Supplement to be filed with the Commission. We have also examined and relied upon the Underwriting Agreement, minutes of meetings of the stockholders and the Board of
Biodel Inc.
June 19, 2013
Page 2
Directors of the Company, including committees thereof, each as provided to us by the Company, the Certificate of Incorporation and Bylaws of the Company, each as restated and/or amended to date, and such other documents as we have deemed necessary for purposes of rendering the opinion hereinafter set forth.
In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all signatories to such documents.
We express no opinion herein as to the laws of any state or jurisdiction other than the state laws of the State of New York, the General Corporation Law of the State of Delaware and the federal laws of the United States of America.
Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when issued and paid for in accordance with the terms and conditions of the Underwriting Agreement, the Shares will be validly issued, fully paid and non-assessable.
Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.
We hereby consent to the filing of this opinion in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act with the Commission as an exhibit to the Current Report on Form 8-K to be filed by the Company in connection with the issue and sale of the Shares and to the use of our name in the Prospectus Supplement under the caption “Legal Matters.” In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.
Very truly yours,
/s/ HAND BALDACHIN & AMBURGEY LLP
HAND BALDACHIN & AMBURGEY LLP
